Articles tagged with Cancer Medication
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
A new study describes a compound that selectively kills cancer cells by restoring the structure and function of mutant p53. This finding supports the development of rationally targeted cancer therapies and has potential for treating 30,000 patients annually in the US.
Researchers found no link between beta blocker use and colorectal cancer risk, even after considering patient characteristics. Long-term use or subtypes of beta blockers showed no reduction in colorectal cancer risk.
Scientists at UTHealth Medical School have made a key discovery in cell signaling relevant to the fight against melanoma skin cancer. They found that BRaf inhibitors, widely used to treat melanomas, can actually enhance abnormal signaling activity when applied to cells with Ras mutations.
Researchers at the University of Pittsburgh Cancer Institute have identified a molecule activated by a virus that can selectively kill tumor cells in animal studies. A new drug candidate, YM155, has shown promising results in killing MCC cells and suppressing tumor growth.
Researchers at IBN developed a miniaturized biochip, Droplet Array, to study the effect of drugs on cancer stem cells (CSCs). The new technology shows CSCs can survive chemotherapy and drive metastasis, highlighting the need for more effective cancer drugs.
Researchers have developed a potent new drug called Lys05 that kills tumor cells in mouse models by clogging their recycling system. This approach has shown promise as a single-agent anti-tumor therapy with minimal toxicity to healthy cells.
A new study launched by University of Leicester is exploring whether tablets containing curcumin can enhance the effectiveness of chemotherapy for advanced bowel cancer. The trial aims to recruit 40 patients and investigate the safety and efficacy of adding curcumin to standard treatment.
Researchers at Washington University School of Medicine identified a cancer drug, idarubicin, that enhances the human body's innate antiviral system. The new strategy screens large numbers of existing drugs to find compounds that activate genes boosting natural immunity.
A $4.5 million grant will fund the search to find new ways of treating glioblastoma multiforme (GBM), the most common type of primary brain tumors. The study aims to discover new medicines that can precisely target tumors, shrinking or eliminating them with minimal harm.
Researchers at the University of Georgia found that long-term lack of oxygen in cells may be a key driver of cancer growth. Cancer cells switch to glycolysis for energy production, leading to a vicious cycle of increased hunger and growth.
A new analysis by French researchers identified patients with low phosphatidylinositol 3-kinases (PI3K) levels and low expression of the protein LKB1 as likely to benefit from everolimus treatment in breast cancer, contradicting initial hypotheses.
Researchers at IDIBELL discovered that combining two mTOR inhibitors can stop liver cancer growth and destroy tumor cells. A clinical trial is underway to evaluate the efficacy of this combination in humans.
A UNC study successfully delivers therapeutic doses of a cancer drug using nanoparticle carriers, overcoming pharmacologic challenges that led to its abandonment. The study demonstrates improved efficacy and reduced toxicity for the abandoned drug.
A landmark study found that bevacizumab (Avastin) is equivalent to ranibizumab (Lucentis) in treating wet age-related macular degeneration through two years, with monthly dosing producing slightly more vision gain. The study showed similar visual results regardless of dosing frequency, with 60% of patients achieving driving vision.
A new study found that only 6% of breast cancer survivors experience persistent and debilitating fatigue a year after treatment, contradicting previous reports. The researchers suggest that factors unrelated to the cancer or its treatment may have contributed to the high rates of reported fatigue.
The Journal of the National Cancer Institute warns that dietary supplements may lower cancer risk, but only observational studies support this claim. Randomized controlled trials show no correlation between supplement use and reduced cancer risk.
The Domino technology, developed at the University of Alberta, enables fast and accurate genetic testing using a miniaturized plastic chip. The innovation has the potential to transform point-of-care medicine, making it possible to screen large populations in a short time.
A new study published in PLoS ONE found that anxious mice developed more severe cancer than calm counterparts, with accelerated tumor growth and invasive cancer. The researchers discovered that anxiety is linked to increased levels of immune-suppressing cells and a dampened immune system.
Researchers from IMIM and UPF identified 115 proteins in silico that could be highly relevant to treat colon-rectal cancer, enabling the design of new generation anti-cancer drugs. The study uses a computational method to predict proteins that interact with molecules showing differential cytotoxicity.
Researchers at Vetmeduni Vienna have shown that chronic myeloid leukaemia (CML) and B-cell acute lymphoid leukaemia (B-ALL) arise from the same long-term haematopoietic stem cells. Understanding this finding is crucial for developing targeted therapies, as current treatments may not effectively target cancer stem cells.
A recent shortage of prescription generic drugs in Canada has highlighted the issue for two years, with up to 98% of pharmacists experiencing shortages during working shifts. The problem is exacerbated by the affordability issues faced by 10% of Canadians who rely on these medications.
Researchers at the University of Warwick discovered the precise mechanism by which spindle checkpoint proteins bind chromosomes. This breakthrough understanding could lead to the development of more selective and effective cancer drugs, potentially reducing debilitating side effects.
Researchers have reclassified breast cancer into 10 subtypes based on genetic features, allowing doctors to predict tumor behavior and tailor treatment. The study also discovered several completely new genes linked to breast cancer, which could lead to the development of new drugs and treatments.
The Clinical Research Forum announced Top 10 Clinical Research Achievement Awards for outstanding projects tackling difficult health problems, including disease prevention, cystic fibrosis, leukemia, and cardiovascular disease. The top prize was awarded for HIV transmission prevention through early treatment.
Scientists are developing new medicines based on epigenetics, a quiet revolution in biology and chemistry that influences how genes work in health and disease. Four drugs approved for blood cancer have limitations due to lack of selectivity.
Researchers at Case Western Reserve University have developed a magnetic nanochain delivery system that explodes chemotherapy drugs inside tumors, killing cancer cells more efficiently. The technology reduced tumor growth by up to 90% and increased survival rates in rats with triple-negative breast cancer.
Researchers used live microscopy to observe how cancer cells react to chemotherapy in different tumor microenvironments. Selective inhibition of certain enzymes and immune signaling molecules made breast tumors more responsive to doxorubicin, a widely used chemotherapeutic agent.
A new study finds that immunotherapy can be effective in elderly cancer patients when combined with a specific treatment targeting age-related immune suppressor cells. The approach offers less toxic effects and improved outcomes compared to traditional therapies.
Researchers have discovered that activating mutations in the FLT3 gene play a crucial role in acute myeloid leukemia, making it an attractive target for new treatments. The study identifies drug-resistant mutations in FLT3 and suggests that therapies involving combinations of multiple drugs could suppress these mutated forms.
A web-based intervention tool called Guide to Decide helped post-menopausal women understand their breast cancer options and feel comfortable with their choice, leading to less uncertainty and increased decision-making. The study found that tailored information reduced anxiety and improved decision outcomes for high-risk women.
A University of Miami study shows that physically active women with non-metastatic breast cancer experience reduced depression and fatigue, as well as improved quality of life. Women who engaged in regular physical activity reported less debilitating fatigue and an enhanced ability to perform daily activities.
Researchers at Case Western Reserve University identified a set of master switches, called Variant Enhancer Loci (VELs), that regulate key genes in colon cancer. VELs are epigenetic changes that can potentially be reversed and may play a role in determining individual susceptibility to colon cancer.
A study by Michigan Oncology Quality Consortium found that most practices followed guidelines for breast, colorectal, and lung cancers, but had gaps in managing symptoms and end-of-life care. To improve quality, the consortium initiated a project to provide palliative care delivery.
Researchers develop new methods for injecting drugs and genetic payloads directly into cancer cells using plasmonic nanobubbles. Delivering chemotherapy with nanobubbles increases efficacy and reduces dosage, targeting single-cell level cancer treatment.
A new report by American Cancer Society scientists reveals that daily low-dose aspirin use may lower overall cancer incidence and mortality. The study found a significant reduction in cancer death, even at doses as low as 75 mg daily.
Researchers identified hundreds of novel genes mutated in stomach cancer, which could lead to targeted therapies. FAT4 and ARID1A were found to be particularly interesting, with mutations detected in 5% and 8% of stomach cancers, respectively.
Northwestern University scientists develop gold nanostars that target cancer cells' nucleus, releasing a killing drug. The nanoparticles are attracted by a protein on the surface and change shape after drug release, causing cell death.
A McGill University team has developed a new microarray technology that can accurately measure multiple proteins in a droplet of blood to detect breast cancer. The test, which uses a 'fingerprint' approach, showed promise in classifying patients with estrogen receptor-positive breast cancer.
BIND Biosciences presents late-breaker clinical data for BIND-014, a targeted docetaxel Accurin, showing anti-tumor activity in six of 17 patients with advanced or metastatic solid tumor cancers. The study demonstrated partial response or stable disease with durable responses of up to six months.
Researchers at Fox Chase Cancer Center have developed a new approach to overcome drug resistance in colorectal cancer patients. Their novel drug, ARI-4175, has shown promise in extending survival by enlisting the body's own immune system to reject tumors.
Researchers have successfully tested the first targeted cancer drug called BIND-014, demonstrating its ability to target receptors in tumors and achieve high tumor concentrations. The study shows remarkable efficacy, safety, and pharmacological properties compared to traditional chemotherapy.
A University of Colorado Cancer Center study found that men taking crizotinib for lung cancer experience a significant drop in testosterone levels, which can lead to fatigue, low bone density, and decreased sex drive. Regular monitoring and treatment of testosterone deficiency can improve patients' overall quality of life.
BIND-014, a novel Accurin nanoparticle, demonstrates high drug concentration in tumors and promising clinical effects in advanced or metastatic cancers. Preclinical data show up to ten-fold increase in intratumoral drug concentrations with prolonged tumor growth suppression.
A study by Dana-Farber Cancer Institute reveals that rapamycin triggers diabetic-like symptoms in some patients through activity of protein YY1. The researchers found that mice without the YY1 protein were protected against the effects, raising caution about the use of rapamycin.
A new drug developed by Northwestern Medicine scientists has prevented human prostate cancer cells from spreading to other tissues. The drug inhibits movement of the cells and prevents metastasis without causing harm to normal cells or tissues.
Rapamycin, a widely used cancer and transplant drug, leads to diabetes in 15% of patients due to its effect on muscle cells' insulin signal. Researchers discovered that a single transcription factor, YY1, plays a key role in this process. Mice lacking YY1 are protected from diabetes when taking rapamycin.
Researchers at Fox Chase Cancer Center have identified a new compound that targets a key pathway in lymphoma, suggesting it could be the first to hit this critical mechanism. The study found that certain types of lymphoma cells are more vulnerable to the effects of the compound, making them potential candidates for early clinical trials.
A harmless human virus, RT3D, has shown promise in boosting the effects of chemotherapy drugs in advanced head and neck cancer patients. In a Phase I/II trial, approximately one-third of patients experienced tumor shrinkage and disease stabilization.
A study found that adding cetuximab to a regimen of drugs after stage III colon cancer surgery did not improve disease-free survival. The trial tested the combination in patients with resected stage III wild-type KRAS colon cancer and showed no benefit.
Scientists at Fox Chase Cancer Center have discovered compounds that enhance the effects of gemcitabine, improving its ability to kill pancreatic cancer cells. This breakthrough could lead to a lower dose of chemotherapy with fewer side effects, potentially increasing survival rates for patients.
Scientists at Fox Chase Cancer Center found that defects in ribosomal proteins can lead to blood and other cancers. Inactivating L22, a key protein, triggered changes in cell signaling pathways associated with inflammation, which may be targeted for cancer treatment.
A new non-invasive technology, stool DNA (sDNA) testing, is being studied in a five-year clinical trial to detect colon cancer in its earliest stages. The test aims to improve colon cancer screening rates and decrease mortality from the deadly disease by complementing colonoscopy.
Dr. Eric N. Olson, chairman of molecular biology at UT Southwestern Medical Center, has been awarded the 2012 Steven C. Beering Award for his work on major genetic pathways controlling heart and muscle formation. Several drugs based on his research are currently under study.
A Mayo Clinic-led study has found that a combination of the novel drug TH-302 with standard drug gemcitabine delays cancer worsening in patients with advanced pancreatic cancer. The 2-drug combo showed a 5.6-month progression-free survival, significantly extending the average survival of six to seven months.
A study by UCLA's Jonsson Comprehensive Cancer Center found that patients with both MEK1 and BRAF mutations respond equally well to BRAF inhibitor drugs, challenging conventional wisdom. The presence of both mutations does not contribute to drug resistance in melanoma patients.
Scientists at WashU Medicine are using DNA sequencing to map the genetic evolution of disease and monitor response to treatment. By analyzing tumor samples, they can identify 'driver' mutations and determine whether cells carrying those mutations have been eliminated by treatment.
Researchers identified pazopanib as a clinically meaningful treatment for refractory urothelial cancer. The study found that increases in interleukin-8 levels after treatment predicted a lack of tumor response, with 10% of patients experiencing long-term cure.
A Phase 1 study demonstrated galeterone's tolerability and efficacy in patients with castration-resistant prostate cancer, with minimal toxicities reported. The study showed significant reductions in tumor size and prostate-specific antigen levels in nearly half of the patients evaluated.
Galeterone, a small-molecule oral drug, demonstrated limited side effects and reduced prostate-specific antigen expression in patients with castration-resistant prostate cancer. The drug's triple mechanism of action showed promise in blocking the growth of prostate cancer cells.
Researchers found that metformin reduces the level of glucose and inhibits fatty acid synthesis in mice, resulting in significantly fewer and smaller liver tumors. The drug has been linked to reduced risk of liver cancer in patients with Type II diabetes and obesity.